Guidelines, Recommendations and Essential Reviews

Edited by: Hector Mora (School of Medical Sciences, Aberdeen, U.K.) h.mora@abdn.ac.uk and Sybren de Hoog (Centraalbureau voor Schimmelcultures, Utrecht, The Netherlands) de.hoog@cbs.knaw.nl .

AmBisome®: adds to the body of knowledge and familiarity of use
(Richardson, Acta Biomed, 77, Suppl. 4: 3-11, 2007).

Amphotericin B: spectrum and resistance
(Ellis, J. Antimicrob. Chemother. 49, Suppl 1: 7-10, 2002)

Antifungal agents.
(Chen & Sorrell, MJA 187: 404-409, 2007).

Antifungal resistance mechanisms of Aspergillus.
(Qiao et al., Jpn. J. Med. Mycol. 49, 157-163, 2008).

From Attachment to Invasion: Infection Associated Genes of Candida albicans 
(Zakikhany et al., Jpn. J. Med. Mycol. 49: 245-251, 2008)

Biodiversity of the genus Cladophialophora.
(Badali et al., Stud. Mycol. 61: 175-191, 2008).

Candida albicans-Endothelial Cell Interactions: a Key Step in the Pathogenesis of Systemic Candidiasis
(Grubb et al., Infect. Immun. 76: 4370-4377, 2008).

Caspofungin: the first representative of a new antifungal class
(Letscher-Bru & Herbrecht, J. Antimicrob. Chemother. 51: 513-521, 2003)

Clinical Practice Guidelines for the Management of Blastomycosis
(Stanley et al., CID 46: 1801-1812, 2008).

Clinical spectrum of Scedosporium
(Guarro et al., Med. Mycol. 44: 295-327, 2006).

NEW Clonal populations of Penicillium marneffei in Thailand reveal low effective dispersal.
(Fisher et al., PLOS Pathogens 1: 159-165, 2005).      

Definitions of invasive fungal disease
(De Pauw et al., CID 46: 1813-1821, 2008).

Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria
(Segal et al., CID 47: 674-683, 2008).

Diagnosis of invasive fungal infections in hematology and oncology
(Ruhnke et al., Ann Hematol (2003) 82 (Suppl 2):S141–S148)

Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial
(Pagani et al., JAC 50: 231-240, 2002)

EUCAST_Technical Notes on Voriconazole testing_CMI 2008
(Clin Microbiol Infect 2008; 14: 985–987)

Galactomannan in Bronchoalveolar Lavage Fluid
(Meersseman et al., Am J Respir Crit Care Med 177: 27–34, 2008)

Fungal invasion of normally non-phagocytic host cells.  
(Filler & Sheppard, PLOS Pathogens 2: 1099-1105, 2006).

Genomics of Aspergillus oryzae: Learning from the history of Koji Mold and exploration of Its future

(Machida et al., DNA Res. 15: 173-183, 2008)

Guidelines for treatment of onychomycosis
(Roberts et al.: Br. J. Dermatol 148: 402–410, 2003)

Invasive fungal infections: a review of epidemiology and management options
(Enoch et al., J. Med. Microbiol. 55: 809-818, 2006).

Management of blastomycosis
(Chapman et al., CID 46: 1801-1812, 2008).

Mechanisms of resistance to antifungal agents: Yeasts and filamentous fungi
(Espinel-Ingroff, Revta Iberoam. Micol. 25: 101-106, 2008).

New and emerging treatments for fungal infections.
(Pasqualotto & Denning, J. Antimicrob. Chemotherap. 61, Suppl. 1, i19-i30, 2008).

Multilocus Sequence Typing of Pathogenic Candida Species
(Odds & Jacobsen, Eukaryot. Cell 7: 1075-1084, 2008).

Nomenclature of fungal disease
(Odds et al., J. Med. Vet. Mycol. 30: 1-10, 1992).

Pneumocystis Pneumonia
(Lu et al., Formos. Med. Assoc. 107: 830-842, 2008).  

Primary cerebral infections
(Horré & de Hoog, Stud. Mycol. 43: 194-205, 1999).

Phenotypic switching in Cryptococcus neoformans
(Guerrero et al.,  Microbiology 152: 3-9, 2006).

Practice Guidelines for the Treatment of Fungal Infections
(Sobel et al., CID 30: 652, 2000)

Rhodotorula infection. A systematic review of 128 cases from literature. 
(Tuon & Costa, Revta Iberoam. Micol. 25: 135-140, 2008).

Role of macrophages in host defense against aspergillosis and strategies for immune augmentation
(Segal, Oncologist 12, Suppl. 2, 7-13, 2007).

Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
(Leah & Steinbach, Eukaryotic Cell 7: 747-764, 2007).

Treatment of aspergillosis
(Walsh et al., CID 46: 327-360, 2008).

Treatment of invasive candidal infections: systematic review and meta-analysis.
(Gafter-Gvili et al., Mayo Clin. Proc. 83: 1011-1021, 2008).

Treatment of invasive fungal infections in adults
(Flückiger et al., Swiss Med. Weekly 136: 447-463, 2006).

Trends in the epidemiology of invasive fungal infections.
(Warnock, Jpn. J. Med. Mycol. 48: 1-12, 2007).